An institutional strategy to increase minority recruitment to therapeutic trials

Victoria V. Anwuri, Lannis E. Hall, Katherine Mathews, Brian C. Springer, Jennifer R. Tappenden, Dione M. Farria, Sherrill Jackson, Melody Goodman, Timothy J. Eberlein, Graham A. Colditz

Research output: Contribution to journalArticle

Abstract

Purpose: Participation in therapeutic clinical trials rarely reflects the race and ethnic composition of the patient population. To meet National Institutes of Health-mandated goals, strategies to increase participation are required. We present a framework for institutional enhancement of minority clinical trial accrual. Methods: We implemented structural changes on four levels to induce and sustain minority accrual to clinical trials: (1) leadership support; (2) center-wide policy change; (3) infrastructural process control, data analysis, and reporting; and (4) follow-up with clinical investigators. A Protocol Review and Monitoring Committee reviews studies and monitors accrual, and the Program for the Elimination Cancer Disparities leads efforts for proportional accrual, supporting the system through data tracking, Web tools, and feedback to investigators. Results: Following implementation in 2005, minority accrual to therapeutic trials increased from 12.0 % in 2005 to 14.0 % in 2010. The "rolling average" minority cancer incidence at the institution during this timeframe was 17.5 %. In addition to therapeutic trial accrual rates, we note significant increase in the number of minorities participating in all trials (therapeutic and nontherapeutic) from 2005 to 2010 (346-552, 60 % increase, p < 0.05) compared to a 52 % increase for Caucasians. Conclusions: Implementing a system to aid investigators in planning and establishing targets for accrual, while requiring this component as a part of annual protocol review and monitoring of accrual, offers a successful strategy that can be replicated in other cancer centers, an approach that may extend to other clinical and translational research centers.

Original languageEnglish (US)
Pages (from-to)1797-1809
Number of pages13
JournalCancer Causes and Control
Volume24
Issue number10
DOIs
StatePublished - Oct 2013

Fingerprint

Research Personnel
Clinical Trials
Neoplasms
Translational Medical Research
National Institutes of Health (U.S.)
Advisory Committees
Therapeutics
Information Systems
Research Design
Incidence
Population

Keywords

  • Clinical trial
  • Disparities
  • Enrollment
  • Minority
  • Participation
  • Therapeutic trial

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Anwuri, V. V., Hall, L. E., Mathews, K., Springer, B. C., Tappenden, J. R., Farria, D. M., ... Colditz, G. A. (2013). An institutional strategy to increase minority recruitment to therapeutic trials. Cancer Causes and Control, 24(10), 1797-1809. https://doi.org/10.1007/s10552-013-0258-1

An institutional strategy to increase minority recruitment to therapeutic trials. / Anwuri, Victoria V.; Hall, Lannis E.; Mathews, Katherine; Springer, Brian C.; Tappenden, Jennifer R.; Farria, Dione M.; Jackson, Sherrill; Goodman, Melody; Eberlein, Timothy J.; Colditz, Graham A.

In: Cancer Causes and Control, Vol. 24, No. 10, 10.2013, p. 1797-1809.

Research output: Contribution to journalArticle

Anwuri, VV, Hall, LE, Mathews, K, Springer, BC, Tappenden, JR, Farria, DM, Jackson, S, Goodman, M, Eberlein, TJ & Colditz, GA 2013, 'An institutional strategy to increase minority recruitment to therapeutic trials', Cancer Causes and Control, vol. 24, no. 10, pp. 1797-1809. https://doi.org/10.1007/s10552-013-0258-1
Anwuri VV, Hall LE, Mathews K, Springer BC, Tappenden JR, Farria DM et al. An institutional strategy to increase minority recruitment to therapeutic trials. Cancer Causes and Control. 2013 Oct;24(10):1797-1809. https://doi.org/10.1007/s10552-013-0258-1
Anwuri, Victoria V. ; Hall, Lannis E. ; Mathews, Katherine ; Springer, Brian C. ; Tappenden, Jennifer R. ; Farria, Dione M. ; Jackson, Sherrill ; Goodman, Melody ; Eberlein, Timothy J. ; Colditz, Graham A. / An institutional strategy to increase minority recruitment to therapeutic trials. In: Cancer Causes and Control. 2013 ; Vol. 24, No. 10. pp. 1797-1809.
@article{d5f232134d56444cb8bb4a0033270440,
title = "An institutional strategy to increase minority recruitment to therapeutic trials",
abstract = "Purpose: Participation in therapeutic clinical trials rarely reflects the race and ethnic composition of the patient population. To meet National Institutes of Health-mandated goals, strategies to increase participation are required. We present a framework for institutional enhancement of minority clinical trial accrual. Methods: We implemented structural changes on four levels to induce and sustain minority accrual to clinical trials: (1) leadership support; (2) center-wide policy change; (3) infrastructural process control, data analysis, and reporting; and (4) follow-up with clinical investigators. A Protocol Review and Monitoring Committee reviews studies and monitors accrual, and the Program for the Elimination Cancer Disparities leads efforts for proportional accrual, supporting the system through data tracking, Web tools, and feedback to investigators. Results: Following implementation in 2005, minority accrual to therapeutic trials increased from 12.0 {\%} in 2005 to 14.0 {\%} in 2010. The {"}rolling average{"} minority cancer incidence at the institution during this timeframe was 17.5 {\%}. In addition to therapeutic trial accrual rates, we note significant increase in the number of minorities participating in all trials (therapeutic and nontherapeutic) from 2005 to 2010 (346-552, 60 {\%} increase, p < 0.05) compared to a 52 {\%} increase for Caucasians. Conclusions: Implementing a system to aid investigators in planning and establishing targets for accrual, while requiring this component as a part of annual protocol review and monitoring of accrual, offers a successful strategy that can be replicated in other cancer centers, an approach that may extend to other clinical and translational research centers.",
keywords = "Clinical trial, Disparities, Enrollment, Minority, Participation, Therapeutic trial",
author = "Anwuri, {Victoria V.} and Hall, {Lannis E.} and Katherine Mathews and Springer, {Brian C.} and Tappenden, {Jennifer R.} and Farria, {Dione M.} and Sherrill Jackson and Melody Goodman and Eberlein, {Timothy J.} and Colditz, {Graham A.}",
year = "2013",
month = "10",
doi = "10.1007/s10552-013-0258-1",
language = "English (US)",
volume = "24",
pages = "1797--1809",
journal = "Cancer Causes and Control",
issn = "0957-5243",
publisher = "Springer Netherlands",
number = "10",

}

TY - JOUR

T1 - An institutional strategy to increase minority recruitment to therapeutic trials

AU - Anwuri, Victoria V.

AU - Hall, Lannis E.

AU - Mathews, Katherine

AU - Springer, Brian C.

AU - Tappenden, Jennifer R.

AU - Farria, Dione M.

AU - Jackson, Sherrill

AU - Goodman, Melody

AU - Eberlein, Timothy J.

AU - Colditz, Graham A.

PY - 2013/10

Y1 - 2013/10

N2 - Purpose: Participation in therapeutic clinical trials rarely reflects the race and ethnic composition of the patient population. To meet National Institutes of Health-mandated goals, strategies to increase participation are required. We present a framework for institutional enhancement of minority clinical trial accrual. Methods: We implemented structural changes on four levels to induce and sustain minority accrual to clinical trials: (1) leadership support; (2) center-wide policy change; (3) infrastructural process control, data analysis, and reporting; and (4) follow-up with clinical investigators. A Protocol Review and Monitoring Committee reviews studies and monitors accrual, and the Program for the Elimination Cancer Disparities leads efforts for proportional accrual, supporting the system through data tracking, Web tools, and feedback to investigators. Results: Following implementation in 2005, minority accrual to therapeutic trials increased from 12.0 % in 2005 to 14.0 % in 2010. The "rolling average" minority cancer incidence at the institution during this timeframe was 17.5 %. In addition to therapeutic trial accrual rates, we note significant increase in the number of minorities participating in all trials (therapeutic and nontherapeutic) from 2005 to 2010 (346-552, 60 % increase, p < 0.05) compared to a 52 % increase for Caucasians. Conclusions: Implementing a system to aid investigators in planning and establishing targets for accrual, while requiring this component as a part of annual protocol review and monitoring of accrual, offers a successful strategy that can be replicated in other cancer centers, an approach that may extend to other clinical and translational research centers.

AB - Purpose: Participation in therapeutic clinical trials rarely reflects the race and ethnic composition of the patient population. To meet National Institutes of Health-mandated goals, strategies to increase participation are required. We present a framework for institutional enhancement of minority clinical trial accrual. Methods: We implemented structural changes on four levels to induce and sustain minority accrual to clinical trials: (1) leadership support; (2) center-wide policy change; (3) infrastructural process control, data analysis, and reporting; and (4) follow-up with clinical investigators. A Protocol Review and Monitoring Committee reviews studies and monitors accrual, and the Program for the Elimination Cancer Disparities leads efforts for proportional accrual, supporting the system through data tracking, Web tools, and feedback to investigators. Results: Following implementation in 2005, minority accrual to therapeutic trials increased from 12.0 % in 2005 to 14.0 % in 2010. The "rolling average" minority cancer incidence at the institution during this timeframe was 17.5 %. In addition to therapeutic trial accrual rates, we note significant increase in the number of minorities participating in all trials (therapeutic and nontherapeutic) from 2005 to 2010 (346-552, 60 % increase, p < 0.05) compared to a 52 % increase for Caucasians. Conclusions: Implementing a system to aid investigators in planning and establishing targets for accrual, while requiring this component as a part of annual protocol review and monitoring of accrual, offers a successful strategy that can be replicated in other cancer centers, an approach that may extend to other clinical and translational research centers.

KW - Clinical trial

KW - Disparities

KW - Enrollment

KW - Minority

KW - Participation

KW - Therapeutic trial

UR - http://www.scopus.com/inward/record.url?scp=84884595526&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884595526&partnerID=8YFLogxK

U2 - 10.1007/s10552-013-0258-1

DO - 10.1007/s10552-013-0258-1

M3 - Article

VL - 24

SP - 1797

EP - 1809

JO - Cancer Causes and Control

JF - Cancer Causes and Control

SN - 0957-5243

IS - 10

ER -